Cingulate Inc (CING) - Total Liabilities
Based on the latest financial reports, Cingulate Inc (CING) has total liabilities worth $12.56 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore CING cash flow conversion to assess how effectively this company generates cash.
Cingulate Inc - Total Liabilities Trend (2019–2025)
This chart illustrates how Cingulate Inc's total liabilities have evolved over time, based on quarterly financial data. Check financial resilience of Cingulate Inc to evaluate the company's liquid asset resilience ratio.
Cingulate Inc Competitors by Total Liabilities
The table below lists competitors of Cingulate Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Scherzer & Co. AG
F:PZS
|
Germany | €8.01 Million |
|
Daebo Magnetic Co.Ltd
KQ:290670
|
Korea | ₩29.68 Billion |
|
Norcod As
OL:NCOD
|
Norway | Nkr335.97 Million |
|
Cobre Ltd
AU:CBE
|
Australia | AU$6.80 Million |
|
Tailyn Technologies
TWO:5353
|
Taiwan | NT$654.00 Million |
|
Delta Technologies Nyrt
BUD:DELTA
|
Hungary | Ft10.84 Billion |
|
Defense Metals Corp
V:DEFN
|
Canada | CA$1.55 Million |
|
Dawson Geophysical Company
NASDAQ:DWSN
|
USA | $25.39 Million |
Liability Composition Analysis (2019–2025)
This chart breaks down Cingulate Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Cingulate Inc market cap and net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.16 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 5.01 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.83 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Cingulate Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Cingulate Inc (2019–2025)
The table below shows the annual total liabilities of Cingulate Inc from 2019 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $12.56 Million | +69.58% |
| 2024-12-31 | $7.41 Million | -28.49% |
| 2023-12-31 | $10.36 Million | +37.72% |
| 2022-12-31 | $7.52 Million | +268.29% |
| 2021-12-31 | $2.04 Million | -54.56% |
| 2020-12-31 | $4.50 Million | -3.64% |
| 2019-12-31 | $4.66 Million | -- |
About Cingulate Inc
Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products using its drug delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company's lead product candidate is CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials for the treatment of ADHD in children, adolescents, and adults. It … Read more